ALDX — Aldeyra Therapeutics Balance Sheet
0.000.00%
- $168.31m
- $82.19m
Annual balance sheet for Aldeyra Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 77.9 | 230 | 174 | 143 | 101 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 83.1 | 233 | 181 | 148 | 104 |
Net Property, Plant And Equipment | 0.293 | 0.384 | 0.269 | 0.517 | 0.267 |
Other Long Term Assets | |||||
Total Assets | 83.4 | 233 | 181 | 148 | 105 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 12.4 | 11.8 | 15.4 | 22.3 | 18.6 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 23.8 | 27.4 | 30.3 | 28.5 | 33.6 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 59.5 | 206 | 151 | 120 | 71 |
Total Liabilities & Shareholders' Equity | 83.4 | 233 | 181 | 148 | 105 |
Total Common Shares Outstanding |